News & Events
-
May 16, 2022
The Critical Path for Parkinson’s Consortium Welcomes ESCAPE Bio
The Critical Path for Parkinson’s Consortium (CPP) is thrilled to welcome our newest member, ESCAPE Bio, a clinical-stage company developing novel, precisely targeted therapies for genetic neurodegenerative diseases. We applaud ESCAPE Bio for their willingness to share data, consistent with CPP’s open science strategy for advancing drug development tools for Parkinson’s disease trials. -
March 28, 2022
C-Path is proud to share our responses to the FDA draft guidance, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations
The Clinical Outcomes Assessment (COA), Critical Path for Parkinson’s Digital Drug Development (3DT) Initiative, and Type 1 Diabetes (T1D) Consortia all contributed to this effort, resulting in a combined set of comments on behalf of C-Path. By bringing together stakeholders across industry, regulatory agencies, patient groups, academic researchers and clinicians, disease foundations and other organizations... -
November 30, 2021
Critical Path for Parkinson’s Shares Internship Highlights from Mikayla Spott
Critical Path for Parkinson’s is proud to highlight Mikayla Spott who joined the team as CPP’s first consortium intern in August 2020. CPP was glad to play a part in her journey toward pursuing her dream of becoming a physician (and celebrates her recent acceptance to multiple medical schools!). “We are delighted to share her story and hope... -
July 20, 2021
Digital Health Technologies Hold Key to New Parkinson’s Treatments
Global stakeholders come together to collaborate with urgency to address unmet needs for Parkinson’s therapies. TUCSON, Ariz., July 20, 2021 — The use of digital health technologies across health care and drug development has accelerated. A new paper titled “Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective,” co-authored by experts across... -
March 18, 2021
Welcome Dr. Martijn Muller as CPP Senior Scientific Director
C-Path is pleased to welcome Martijn Muller, PhD, as Senior Scientific Director for the Critical Path for Parkinson Consortium. Prior to joining C-Path, Martijn was Research Associate Professor of Radiology and Co-Director of the Clinical and Neuroimaging Resource Cores of the Udall Center of Excellence for Parkinson’s disease Research at the University of Michigan. Dr. Muller has a diverse research background with an established publication record in neuropsychology, biomechanics, and neuroimaging.